Stocks
Cassava Sciences Inc Financial Statements (SAVA) |
||||||||||
| Cassava Sciences Incsmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 26.03.2020 | 23.03.2021 | 01.03.2022 | 28.02.2023 | 28.02.2024 | 07.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 0.000 | 0.002 | 0.000 | 2.35 | |||
| Operating Income, bln rub | -4.96 | -6.45 | -32.9 | -80.0 | -106.0 | -140.5 | ||||
| EBITDA, bln rub | ? | -4.57 | -6.31 | -31.9 | -74.9 | -95.7 | -133.5 | |||
| Net profit, bln rub | ? | -4.25 | -5.85 | -31.8 | -72.5 | -97.2 | -17.7 | |||
| OCF, bln rub | ? | -2.51 | -5.38 | -30.2 | -77.5 | -82.0 | -78.0 | |||
| CAPEX, bln rub | ? | 0.018 | 0.000 | 22.2 | 2.71 | 0.414 | 0.087 | |||
| FCF, bln rub | ? | -2.53 | -5.38 | -52.4 | -80.2 | -82.4 | -78.1 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 4.96 | 6.79 | 32.9 | 80.0 | 106.0 | 139.6 | ||||
| Cost of production, bln rub | 0.058 | 0.346 | 0.534 | 1.30 | 89.4 | 0.967 | ||||
| R&D, bln rub | 1.57 | 3.05 | 24.8 | 68.0 | 89.4 | 67.8 | ||||
| Interest expenses, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 2.63 | ||||
| Assets, bln rub | 23.5 | 94.3 | 266.8 | 234.8 | 151.7 | 223.8 | ||||
| Net Assets, bln rub | ? | 22.1 | 92.2 | 253.9 | 227.5 | 137.5 | 166.6 | |||
| Debt, bln rub | 0.090 | 0.293 | 0.236 | 0.139 | 0.000 | 0.000 | ||||
| Cash, bln rub | 23.1 | 93.5 | 233.4 | 201.0 | 121.1 | 149.0 | ||||
| Net debt, bln rub | -23.0 | -93.2 | -233.2 | -200.9 | -121.1 | -149.0 | ||||
| Ordinary share price, rub | 5.20 | 6.82 | 43.7 | 29.5 | 22.5 | 25.8 | ||||
| Number of ordinary shares, mln | 17.4 | 26.1 | 39.4 | 40.2 | 41.9 | 48.0 | ||||
| Market cap, bln rub | 91 | 178 | 1 722 | 1 188 | 944 | 1 235 | ||||
| EV, bln rub | ? | 68 | 85 | 1 489 | 987 | 823 | 1 086 | |||
| Book value, bln rub | 22 | 92 | 253 | 227 | 137 | 167 | ||||
| EPS, rub | ? | -0.24 | -0.22 | -0.81 | -1.80 | -2.32 | -0.37 | |||
| FCF/share, rub | -0.15 | -0.21 | -1.33 | -2.00 | -1.97 | -1.63 | ||||
| BV/share, rub | 1.27 | 3.53 | 6.42 | 5.64 | 3.27 | 3.47 | ||||
| EBITDA margin, % | ? | -4 163 611% | -5 686% | |||||||
| Net margin, % | ? | -4 026 222% | -752.3% | |||||||
| FCF yield, % | ? | -2.80% | -3.02% | -3.04% | -6.76% | -8.73% | -6.32% | |||
| ROE, % | ? | -19.2% | -6.35% | -12.5% | -31.9% | -70.7% | -10.6% | |||
| ROA, % | ? | -18.1% | -6.21% | -11.9% | -30.9% | -64.1% | -7.89% | |||
| P/E | ? | -21.3 | -30.4 | -54.1 | -16.4 | -9.71 | -69.9 | |||
| P/FCF | -35.8 | -33.1 | -32.9 | -14.8 | -11.4 | -15.8 | ||||
| P/S | ? | 659 759 | 526.1 | |||||||
| P/BV | ? | 4.10 | 1.93 | 6.81 | 5.23 | 6.88 | 7.42 | |||
| EV/EBITDA | ? | -14.8 | -13.4 | -46.7 | -13.2 | -8.60 | -8.14 | |||
| Debt/EBITDA | 5.03 | 14.8 | 7.32 | 2.68 | 1.27 | 1.12 | ||||
| R&D/CAPEX, % | 8 711% | 111.7% | 2 509% | 21 600% | 77 975% | |||||
| CAPEX/Revenue, % | 150 667% | 3.71% | ||||||||
| Cassava Sciences Inc shareholders | ||||||||||
